Оценка эффективности обогащенной тромбоцитами аутоплазмы в лечении остеоартроза у пациентов с гиперурикемией

Abstract

Conservative treatment of osteoarthritis includes drugs that cause side effects in the cardiovascular system, gastrointestinal tract, kidneys, and hepatobiliary system. Hence the steadily growing interest in the use of platelet-rich autoplasma as an effective and safe treatment, and it is still an urgent task to estimate its effectiveness in osteoarthritis aggravated by hyperuricemia or gout. The purpose was to estimate the effectiveness of platelet-rich autoplasma in the complex therapy of knee joints osteoarthritis of 2–4 degree (Kellgren — Lawrence, 1987), with concomitant hyperuricemia or gout. The study involved 32 patients (20 women, 12 men, mean age 67 ± 7.8 years, body mass index 32.7 ± 4.8, disease duration 10.3 ± 3.7 months) with knee osteoarthritis and hyperuricemia or gout. All patients of the main group received intra-articular injections of platelet-rich autoplasma during remission. The results were assessed after 1 day, 1 week, 1, 3, 6, and 12 months after the injection using the VAS, Lequesne, and Satisfaction Scales, as well as MRI of the joints after 3 and 6 months after the injection. When compared with traditional medical treatment, the use of PRP did not show a clear benefit, however, this procedure can be recommended as a maintenance procedure to improve the condition of the synovium in patients who have contraindications to non-steroidal anti-inflammatory drugs and glucocorticosteroids. When comparing the results separately in the group of male and female patients, there was a statistically significant improvement in the group of women compared to men.